Effects of chronic treatment with the new ultra-long-acting β2-adrenoceptor agonist indacaterol alone or in combination with the β1-adrenoceptor blocker metoprolol on cardiac remodelling

摘要

Background and PurposeThe ability of a chronic treatment with indacaterol, a new ultra-long-acting β2-adrenoceptor agonist, to reverse cardiac remodelling and its effects in combination with metoprolol, a selective β1-adrenoceptor antagonist, were investigated on myocardial infarction in a rat model of heart failure (HF).